Remus Pharmaceuticals Ltd

NSE:REMUSHealthcare

₹984.50−1.75%At closeAt close · Mon 19 Oct · ≈ AED 38.04 · Market cap $124.22M

INR billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	YoY
Revenue	0.2	0.2	0.5	2.1	6.2	8.5	+37.6%
Cost of revenue	0.1	0.2	0.3	1.7	5.5	7.6	+38.2%
Gross profit	0.0	0.1	0.2	0.4	0.7	0.9	+32.9%
Research & development	0.0	0.0	0.0	0.0	0.0	0.0	—
Operating expenses	0.0	0.0	0.1	0.1	0.3	0.4	+48.8%
Operating income	0.0	0.0	0.1	0.3	0.4	0.5	+23.3%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	+0.7%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	+15.4%
Pre-tax income	0.0	0.0	0.1	0.3	0.5	0.6	+25.0%
Income tax	0.0	0.0	0.0	0.1	0.1	0.1	+45.6%
Net income	0.0	0.0	0.1	0.2	0.3	0.4	+27.2%
EPS, basic (per share)	0.87	2.91	7.22	4.54	24.67	31.39	+27.2%
EPS, diluted (per share)	0.87	2.91	7.22	4.54	24.67	31.39	+27.2%
EBITDA	0.0	0.0	0.1	0.3	0.5	0.6	+24.2%
Depreciation & amortization	0.0	0.0	0.0	0.0	0.0	0.0	+47.6%
Weighted average shares (shares)	11,784,000	11,784,000	11,784,000	45,202,360	11,784,000	11,784,000	+0.0%
Weighted average diluted shares (shares)	11,784,000	11,784,000	11,784,000	45,202,360	11,784,000	11,784,000	+0.0%
Gross margin	20.4%	32.0%	37.0%	18.7%	11.4%	11.0%	−0.4 pts
Operating margin	4.2%	17.1%	23.5%	13.1%	7.1%	6.4%	−0.7 pts
Net margin	5.6%	13.9%	18.9%	9.6%	4.7%	4.3%	−0.4 pts

INR billionsUpdated Tue 31 Mar ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.